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ABSTRACT
The objective of this review is to focus the inferences of low/poor bioavailability and lack of dose proportionality for the oral delivery of drugs in 
prostate cancer therapy. To overcome such problems, various formulation strategies has been reported including various methods for the use of 
surfactants, cyclodextrins, solid dispersions, micronization, permeation enhancers, and lipids. Flutamide is an antiandrogen drug and used for the 
therapy of prostate cancer. The flutamide drug is having limited clinical application due to its poor water solubility and needs enhancement of its 
dissolution rate in simulated gastric fluids. The lipid-based formulations such as nanoemulsion have been shown to improve the solubility and oral 
absorption of lipophilic drugs. To conclude, this article emphasizes the various approaches of nanoemulsion based formulation for prostate cancer 
therapy.
Keywords: Nanoemulsion, Prostate cancer, Flutamide, Antiandrogen drug, Lipophilic drugs.
INTRODUCTION
Cancer is the global risk factor in the current scenario. Mostly cancer 
risks were reported to be due to environmental hazards majorly due 
to air pollutants associated with vehicle smoke, smoke exposure by the 
non-smokers, ultraviolet radiations from sunlight, radon gas exposure, 
asbestos exposure, diesel exhaust pollutants, high arsenic content 
water consumption, and chemicals exposure. The treatment options 
such as surgery, radiation therapy, and chemotherapy were commonly 
practiced for cancer. In this regimen, the current treatment options 
under research includes targeted therapy (with targeting ligands 
focusing specific diseased receptors), immunotherapy, magnetite-
based delivery therapy, light-based therapy (photodynamic therapy), 
ultra sound-based therapy (sonodynamic therapy) using conventional 
nanoparticulate systems such as nanoparticles, nanoemulsions, 
nanodispersions, nanosuspensions, nanomicelles, and siRNA coupled 
combination nanoformulations were utilized. Since there are various 
approaches for the cancer treatments, but the success level is not 
satisfactory, requires retreatments [1].
The transparent/translucent multi-phase colloidal systems composed 
of two immiscible phases (dispersed internal phase (droplets) and 
the other is the continuous external phase) which are only kinetically 
stable and used for the treatment of various ailments were termed as 
nanoemulsions. Nanoemulsions range approximately between 10 and 
500 nm either in oil/water and water/oil forms. Natural, semi-synthetic, 
and synthetic oils were used for the formation of nanoemulsions. In view 
of targeted approach currently biodegradable polymeric nanoparticles, 
hydrogels, micelles, liposomes, microemulsions, nanoemulsions, 
dendrimers, nanoshells, nanotubes, nanomaterials, polymersomes, 
nucleic-acid-based nanoparticles, magnetic nanoparticles, 
polynucleotide nanoparticles, and virus nanoparticles were developed 
and utilized for targeting drugs to the target site of cancerous organs. 
The major components of nanoemulsions include oil, surfactant, and 
cosurfactant. The efficiency of nanoemulsions rely on the smaller size 
of droplets, the larger surface area, the low surface tension of the entire 
system, and the low interfacial tension of the droplets [2].
Whereas, microemulsions a new pharmaceutical interest for 
drug delivery are thermodynamically stable low viscous isotropic 
homogeneous system [3] that can be prepared over a wide range of 
surfactant concentrations in which two immiscible liquids are mixed 
to form a single phase by appropriate surfactant which serves as a 
promising vehicle possessing powerful ability to deliver drugs through 
the skin. Advantages of microemulsions over coarse emulsion include 
spontaneous formation, transparent, enhanced permeation through 
biologic membranes, increased bioavailability and less inter- and intra-
individual variability in drug pharmacokinetics [4]. Several factors 
affect the transdermal drug delivery of microemulsions include the 
affinity of a drug to the internal Phase I microemulsion, ingredients 
reducing the barrier of the stratum corneum, increased concentration 
gradient toward skin and the dispersed phase acting as a reservoir. 
In transdermal delivery, the goal of dosage design is to maximize the 
flux through the skin into systemic circulation. A useful strategy for 
improving percutaneous flux is to improve the concentration of drug 
or by choosing an appropriate vehicle for delivery [5]. However when 
compared to microemulsions, the nanoemulsions were playing a vital 
role for cancer drug delivery recently.
NOVEL PREPARATION METHODS FOR NANOEMULSIONS
To reflect an efficient treatment drugs/bioactive material/bioactive 
proteins may be formulated into nanoemulsions, provided which 
may elicit good bioavailability and enhanced therapeutic response. 
To prepare a stable nanoemulsion proper selection of appropriate 
composition, controlled addition of the components, and application 
of the shear to effectively rupture the droplets are an essential 
criteria [6]. The preparation methods for nanoemulsions includes high-
pressure homogenization (high-pressure homogenizer, at a pressure 
of 50-100 MPa) [7], microfluidization, ultrasonication (ultrasound 
generators), phase inversion method, spontaneous emulsification, 
solvent evaporation technique, and hydrogel method. Among these 
ultrasonic emulsification technique also reduces the droplet size to a 
considerable level, prepared using biodegradable polymers, mostly 
applicable for hydrophobic drugs. Recently, cyclooxgenase-2 inhibiting 
perfluoropoly (ethylene glycol) ether theranostic nanoemulsions has 
been reported by Janjic et al., 2013 to improve the aqueous solubility 
of celecoxib, to attain an enhanced tumor inhibiting effect using 
cremophor EL and PluronicP105 [8]. Fig. 1 summarizes the different 
novel preparation methods for nanoemulsion.
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COMPONENTS OF NANOEMULSION
Their long term physical stability makes them unique and referred 
as approaching chemical stability. The high colloidal nature of the 
nanoemulsion can be studied from a consideration of their stearic 
stabilization and how this is affected by the ratio of absorbed layer 
thickness to droplet radius [9]. An emulsion system is a system which 
is, of which one is the dispersed internal phase (droplets) and the other 
is the continuous external phase. Normally, they are in oil-in-water 
and water-in-oil forms, in which the core may be either oil or water, 
respectively. Nanoemulsions are normally prepared using surfactants 
that are generally considered safe for human consumption by the Food 
and Drug Administration. The type of surfactant and their concentration 
in the aqueous phase are chosen to provide better stability against 
coalescence. Several types of oils (natural, semi-synthetic, and 
synthetic) are used in the formulations of nanoemulsions. The ability 
of nanoemulsions to dissolve a large amount of poorly soluble drugs 
along with their mutual compatibility and capacity to protect the 
drugs from hydrolysis and enzymatic degradation makes them an ideal 
vehicle for drug delivery [10]. Fig. 2 pictures the basic components of 
a nanoemulsion.
OPTIMIZATION OF NANOEMULSIONS FORMATION CAPACITY
To optimize nanoemulsions, the nanoemulsions formation, the pseudo-
ternary phase diagrams comprising oil, surfactants-cosurfactants 
mixture (smix) and double distilled water were utilized using the 
aqueous titration method. Phase diagrams prepared by varying weight 
ratios of surfactant to cosurfactants were used. The ratios were selected 
based on the concentration of surfactants/cosurfactants. For each 
diagram at a particular smix ratio, the ratios of oil to smix are varied. 
The mixture of oil and smix at particular ratios are diluted with water 
drop-wise, under magnetic stirring. The nanoemulsions formation 
capacity were marked on phase diagram with one axis representing the 
aqueous phases, other the oily phase and the next one representing the 
smix at a particular weight ratio [10].
PHARMACEUTICAL APPLICATIONS OF NANOEMULSIONS
In this regimen, the common pharmaceutical applications of 
nanoemulsions were they were considered as a potent vehicle 
for delivery of cosmetics upon skin layers due to its lipophilicity. 
Antimicrobial nanoemulsions composed of oil, water, surfactants, 
and alcohol were used against bacteria), viruses, fungi and spores. 
Nanoemulsion will get fused with lipid-containing organisms and it is 
enhanced by the electrostatic attraction between emulsion opposite 
charges. As a vehicle for the proteins delivery nanoemulsions possesses 
an active role against inactive organisms to the mucosal surfaces to 
produce an immune response. Nanoemulsions are used in the field 
of cell culture for the delivery of various substances to the culture 
medium with the major advantages of transparency; nanosized 
droplets possess the high rate of uptake and cellular bioavailability. As 
a major role in parental drug delivery nanoemulsions serves as an ideal 
vehicle for the transport of drugs because of their ability to dissolve 
the hydrophobic substances and protection from hydrolysis and 
enzymatic degradation. As common phenomena both microemulsions 
and nanoemulsions have their specific applications. Chen et al. 2014 
developed Ganoderma lucidum triterpene loaded microemulsion 
using Coix lacrymajobi seed as oil phase for anti-tumor effect. The 
characterized the developed microemulsions for its size, shape, and 
morphology. The drug loading effect of the developed formulation was 
checked by UV spectrophotometer at 584 nm with an encapsulation 
of around 80.0-84.0%. The anti-proliferative effect of the developed 
microemulsion was checked in A549 cells and found the half maximal 
cytotoxic inhibitory concentration was 0.62 mg/ml of the crude extract. 
The results of their studies concludes that microemulsion based 
formulations can improve the solubility of triterpenes [11]. Han et al. 
(2009) developed novel 10-methoxy-9-nitrocamptothecin (MONCPT) 
nanoemulsion (o/w type) to enhance its solubility, stability, and anti-
tumoractivity. Development of nanoemulsion was achieved using 
lipoid E80 and cremophor EL as main emulsifiers by microfluidization 
method. Solubility and internalization of lactone form of MONCPT in 
nanoemulsion in the interfacial surfactant layer of the nanoemulsion 
was 200-fold higher than in water. MONCPT nanoemulsion shows no 
obvious hemolysis in rabbit erythrocytes. MONCPT nanoemulsion 
showed increased cytotoxicity with the suppression rate of is 93.6%, 
and only 24.2% was observed for MONCPT injection at the same 
dosage. In vivo imaging of tumor in S180-bearing mice evident that 
more accumulation in tumor cells [12].
FLUTAMIDE
Flutamide(2-methyl-N-(4-nitro-3-(trifluoro methyl) phenyl propanamide) 
is a non-steroidal antiandrogenicpoorly water soluble drug competes 
with testosterone and its powerful metabolite, dihydro-testosterone 
binds to androgen receptors in the prostate gland. Flutamide possess the 
capacity to induce the androgen levels in womens, especially those with 
polycystic ovarian syndrome. Flutamide is practically insoluble in water 
(9.45 mg/L) and possess higher hydrophobicity (log P 2.6). Flutamide 
holds poor absorption, dissolution rate, and bioavailability due to its poor 
wettability, low aqueous solubility, poor permeability, rapid first pass 
hepatic metabolism, and low concentration at the absorption surface. 
Lipid-based drug delivery systems (enhancing membrane permeability 
and lymphatic transport) may improve the solubility/bioavailability of 
flutamide. Developing novel formulations may improve the solubility, 
dissolution profile, and cellular uptake/target ability at the diseased 
sites. The common side effects of flutamide include hepatotoxicity, 
nausea, and diarrhea. Flutamide gets metabolized into 2-hydroxy-
flutamide, which also possesses anti-androgenic properties [13,14]. 
Table 1 represents flutamide loaded nanoformulations and its biological 
applications [15-20].
Fig. 1: Novel preparation methods for nanoemulsion
Fig. 2: Basic components of nanoemulsions
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PROSTRATE CANCER
Prostate cancer is a type of cancer which affects the male reproductive 
system with cancerous tissues in the prostate, with altered shape of the 
prostate gland holds the highest incidence among all forms of cancers 
and is the second most deadly cancer in men, even in the US also it has 
been reported to be the second leading cause for cancer-related deaths 
in mens, after lung cancer [21]. The incidence of prostate cancer is high 
at Northern America, Australia, New Zealand, Northern and Western 
Europe. In India also the incidence rate of prostate cancer is at the high-
risk level [22]. Prostate cancer was basically dependent on androgen 
signaling pathway receptor. It is a basic protein composed of 919 
repeated aminoacids sequences such as poly-glutamine, poly-glycine, 
and poly-prolinerepeats of variable lengths. These androgen receptor 
has three major domains such as amino-terminal transcriptional 
activation domain, a DNA-binding domain containing 2 zinc finger 
motifs, and a carboxyl terminal ligand-binding domain which regulates 
the switch by which androgens control the transcriptional activity 
of the receptor. The pathogenesis of prostate cancer greatly depends 
on the alterations in zinc accumulation, alteration of metabolism, and 
citrate production. Altered proteins in the androgen receptor signaling 
leads to altered cellular conditions which may also play an important 
role in prostate cancer pathogenesis. Src signaling based pathway also 
induces androgen-induced prostate cancer cells proliferation. The 
PI3K/PTEN/Akt/mTOR pathway mediates cell survival and neoplastic 
transformation is also constitutes in the development of prostate 
cancer cells, mainly due to the tumor suppressor gene [23]. Moreover, 
prostate cancer cells produce prostatic acid phosphatase, which acts 
on bone remodeling. The pathophysiology indicates that inhibiting 
androgen receptor may be suitable choice to target the prostate 
cancer cells. Zinc is the major contributor for prostate cancer cells 
progression [24]. A study showed that prostate cancer is influenced 
by genetic and several non-genetic factors. The genetic factors include 
genome-wide linkage and association studies have been used to 
identify genomic loci contributing to prostate cancer susceptibility. The 
non-genetic factors are age, family history and obesity [25]. Diet which 
increases the bioavailability of zinc may also the risk factor for prostate 
cancer individuals. The treatment options adopted for prostate cancer 
includes surgery, chemotherapy, radiation therapy, and hormonal 
therapy. Whereas these treatment approaches were not promising and 
they require additional repeated treatments, even the cancer regrowth 
may occur. Therefore treatment options addressing these issues may be 
advantageous in the current scenario.
CURRENT TREATMENT APPROACHES FOR PROSTATE CANCER
Current research trend was focusing various treatment approaches 
for prostate cancer. These treatment modules include various 
nanoparticulate drug delivery systems even coupled with or without 
magnetite or siRNA-based systems. Curcumin (a natural polyphenol) 
due to its multi-acting mechanisms at various sites such as nuclear 
factor-kappa B, transcription factor activator protein-1, mitogen-
activated protein kinase, tumor protein 53, nuclearβ-catenin signaling, 
and AKT signaling pathways has been formulated into nanoparticles 
using cellulose has been reported for the treatment of prostate cancer. 
The cellulose-based curcumin nanoparticles showed the enhanced 
apoptotic effect and utmost cellular uptake mechanism in human 
prostate cancer cell lines (C4-2). These reveal the superior anti-cancer 
effect for the cellulose based curcumin nanoparticles [26]. Dash et al. 
developed multifunctional nanoparticles containing cyclopamine and 
paclitaxel for the treatment of prostate cancer. They entrapped both 
drugs in entrapped in glyceryl mono oleate-chitosan solid lipid as 
well as in poly(glycolic-lactic) acid polymer. The particle size of drug-
loaded glyceryl mono oleate-chitosan nanoparticles was found to be 
278.4±16.4 nm with a positive zeta potential. Whereas, the particle 
size of drug loaded poly(lactic-co-glycolic) acid nanoparticles was 
found to be 234.5±6.8 nm in size with a negative zeta potential. The 
results of their studies confirm that the types of polymer used for the 
nanoparticles preparation plays a vital role and affected the in vitro 
release, cytotoxicity, and uptake of nanoparticles in the all the cell 
lines studied at in vitro level [27]. Thermotherapy using magnetic 
nanoparticles, RGD peptide for the targeted therapy, light based 
photodynamic therapy approach, sonodynamic therapy, photothermal 
destruction using near infra-red light, and magneto oscillatory therapy 
were the current updates for these types of cancer-based treatment 
approaches.
FLUTAMIDE LOADED NANOEMULSION
Flutamide which is a lipophilic drug can be formulated into 
nanoemulsions form using suitable oils, surfactant, and cosurfactant. 
Thereby the problems of poor bioavailability at the required diseased 
site and poor water solubilising capacity can be enhanced. The non-
ionic surfactants which can be used for these formulation approach 
may be selected as poloxamers, polysorbates, spans, vitamin E TPGS, 
solutol HS and polyethoxylated castor oil derivatives. Mono-, di-, and 
tri-glycerides can be selected as oily phase for the nanoemulsion 
formulation. The flutamide loaded nanoemulsions can be formulated 
using polyethylene glycol (using various grades) or grades selected 
based on the conceptual requirements. The clarity of the formulation 
may be assessed. The formulated nanoemulsions can be characterized 
by various in vitro studies (morphology, droplet size) analysis. The 
behavior of the nanoparticles at the cellular level (prostate cancer) 
based cell lines can be assessed. Finally, the bioavailability and anti-
cancer effects of flutamide loaded nanoemulsions can be checked using 
prostate cancer induced animal models. Thus, this type of nano-based 
system which encapsulates flutamide can be the suitable system for the 
treatment of prostate cancer in the near future [28].
TRANSDERMAL NANOEMULSION
Formulations of nano-emulsion for administering protein vaccine with 
artin-M adjuvant were developed. The composition of the formulation 
was 3% virgin coconut oil, 16% Tween 80, 8% polyethylene glycol (PEG) 
400 and deionized water. Bovine serum albumin (BSA) and artin-M 
were incorporated in the oil phase as co-lyophilized solid dispersion in 
PEG 20000 with the optimum ratio of 1:1. The results of nano-emulsion 
formulation indicated the uniform globule diameter formation. Both BSA 
and artin-M were dispersed uniformly in the oil phase during the storage 
with no-aggregation observed in the reconstituted nanoemulsion. These 
studies showed that formulation of nano-emulsion could be used for 
spontaneous delivery of protein vaccine [29].
CURCUMIN NANOEMULSION
The study showed that encapsulation of curcumin in a nano-emulsion 
system is expected to increase the bioavailability of the curcumin after 
Table 1: Flutamide loaded nanoformulations and its biological applications
S. No Nano products Polymers utilized Biological applications References
1. Hydrogels Poly-4-acrylolylmorpholine acrylic acid Anti-cancer effect [15]
2. Lyophilized dispersions Β-cyclodextrin/hydroxypropyl-β-cyclodextrin Prostate cancer treatment [16]
3. Nanoparticles Ionically crosslinked casein Anti-cancer effect [17]
4. Self nanoemulsfying drug delivery system Sesame oil, Tween 20, Poly ethylene glycol 400 Anti-cancer effect [18]
5. Sustained-release matrix tablets Cellulose ethers, natural gums and compressible 
eudragits
Anti-cancer effect [19]
6. Orodispersible tablets Sodium starch glycolate Prostate cancer treatment [20]
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oral administration. In this study, formulation of tablet containing 
curcumin nanoemulsion for oral delivery was evaluated. The study 
results indicated that curcumin nanoemulsion could able to be 
formulated into solid dosage form, with good physical characteristic of 
the tablets [30].
CONCLUSION
Nano-emulsion formulations may holds superior effect (anti-cancer) for 
the treatment of prostate cancer with small size, enhanced cytotoxicity, 
solubilizing the drug, and target ability. It may enhance the bioavailability 
of the drugs at the maximal level when compared to conventional dosage 
forms. Currently, technologies are available for targeting the diseased 
site using multi-functional nano-based systems to avoid the toxicity to 
the healthy cells when compared to the diseased cells.
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